MARKET

IMGN

IMGN

Immunogen Inc
NASDAQ
15.89
-0.27
-1.67%
Opening 13:42 11/28 EST
OPEN
16.12
PREV CLOSE
16.16
HIGH
16.21
LOW
15.67
VOLUME
2.01M
TURNOVER
0
52 WEEK HIGH
20.69
52 WEEK LOW
3.605
MARKET CAP
4.23B
P/E (TTM)
-53.0551
1D
5D
1M
3M
1Y
5Y
The 8.2% return this week takes ImmunoGen's (NASDAQ:IMGN) shareholders one-year gains to 218%
Immunogen, inc. Share price has soared 218% in the last year. The stock is up 197% over three years. Immunogen's revenue has grown by 201%. The company is not currently profitable. The company has added us$325m to its market cap in the past week alone.
Simply Wall St · 1d ago
ImmunoGen: Elahere Data Mid-2024 To Expand Targeted Population
Immunogen, inc. Expects to convert the accelerated approval of its drug elahere to "full approval" in the 1st half of 2024. The drug is approved to treat platinum-resistant ovarian cancer patients. Immunogen expects to be able to expand the use of mirvetuximab to the european union in 2024. A data readout is expected to be released in mid-2024 for the treatment of this type of cancer. Mirvetuxamab can eventually be expanded into another ovarian cancer patient population.
Seeking Alpha · 1d ago
Weekly Report: what happened at IMGN last week (1120-1124)?
Weekly Report · 2d ago
New Strong Buy Stocks for November 22nd
NASDAQ · 11/22 11:23
Goldman starts ImmunoGen at neutral, cites valuation
Goldman sachs starts immunogen at neutral, cites valuation. Investment bank says it is looking for future growth drivers for drug elahere. Goldman sachs set a price target of $17 on the stock of immunogen, inc. (imgn) goldman sachs has a neutral rating.
Seeking Alpha · 11/20 21:28
Where Immunogen Stands With Analysts
6 analysts have an average price target of $22.5 for immunogen (nasdaq:imgn) over the past 3 months. These 6 analysts have provided their ratings for the company in the last quarter. The greater the number of bullish ratings, the more positive analysts are on immunogen.
Benzinga · 11/20 12:00
Goldman Sachs Initiates Coverage On Immunogen with Neutral Rating, Announces Price Target of $17
Benzinga · 11/20 10:03
Weekly Report: what happened at IMGN last week (1113-1117)?
Weekly Report · 11/20 09:03
More
About IMGN
ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Webull offers ImmunoGen, Inc. stock information, including NASDAQ: IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.